GENEDX HOLDINGS CORP. (WGS) Reports the reporting period Financial Results
GENEDX HOLDINGS CORP. (WGS) announced its financial results for the period ending the reporting period.
Key Financial Highlights:
Revenue: 2272
Net Income: 10809
EPS: (0.60)
Cash and equivalents: 61310
Appointed Mark Gardner as President to lead GeneDx’s commercial and operations teams through the next phase of growth, with a focus on strengthening execution, scaling efficiently, and expanding the company’s leadership in genomic medicine.
Launched redesigned exome and genome reports to streamline the delivery of genomic insights to non
genetics clinicians as part of a broader suite of customer experience improvements rolling out this summer.Expanded Coverage for Exome and Genome
📋 GENEDX HOLDINGS CORP. (WGS) - Financial Results
Filing Date: 2026-08-03
Accepted: 2026-08-03 16:14:27
Event Type: Financial Results
Event Details:
📊 Key Financial Metrics (Year-over-Year Comparison):
💼 Business Developments:
Structured Data: